HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)
Open Posted
- Opportunity number
- RFA-DA-27-016
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- Independent School Districts
- County Governments
- For Profit Organizations
- City/Township Governments
- Tribal Governments (Federally Recognized)
- Non-501(c)(3) Nonprofits
- Small Businesses
- Other
- State Governments
- Public or Indian Housing Auth.
- Special District Governments
- Tribal Organizations (Not Federally Recognized)
- 501(c)(3) Nonprofits
- Higher Education Inst. (Public)
- Higher Education Inst. (Private)
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is soliciting applications for the HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice, a phased R61/R33 grant mechanism with a February 9, 2029 application deadline. Participating institutes include the National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Aging (NIA), and National Center for Complementary and Integrative Health (NCCIH).
Eligible applicants include higher education institutions (public and private), 501(c)(3) and non-501(c)(3) nonprofits, for-profit organizations, small businesses, state and local governments, tribal governments and organizations (federally and non-federally recognized), independent school districts, and public or Indian housing authorities. Non-domestic entities and non-domestic components of U.S. organizations are ineligible; foreign components of U.S. organizations are allowed.
The R61 phase supports up to two years of exploratory and planning work at a maximum of $350,000 direct costs annually. The R33 phase provides up to five years of implementation work at a maximum of $750,000 direct costs annually, for a combined period not exceeding six years. Transition from R61 to R33 requires successful completion of specific, quantifiable milestones and administrative NIH review. The NIH intends to commit $6,000,000 to fund approximately 12 awards in FY2027.
Applications must address action-oriented research accelerating translation of addiction epidemiology, prevention, treatment services, and recovery research to practice. Proposed studies may target individual, provider, organizational, community, or system levels, with priority given to replicable and scalable approaches, research relevant to chronic pain comorbid with substance use, and integration of researcher-decision-maker collaboration. Applications must include a Data Management and Sharing Plan, register studies within one year of award, and submit data to HEAL-compliant repositories. Applications focused solely on alcohol or tobacco use disorder, purely prescriptive interventions, or harm reduction approaches are excluded.
Applications undergo scientific peer review followed by National Advisory Council review. Anticipated award dates range from April 2027 through April 2029.
CFDA numbers: 93.279 (Drug Use and Addiction Research Programs), 93.273 (Alcohol Research Programs), 93.213 (Research and Training in Complementary and Integrative Health), and 93.866 (Aging Research).
Synopsis
The goal of this notice of funding opportunity (NOFO) is to address the opioid crisis and/or overdose events by supporting action-oriented research, accelerating the translation of addiction epidemiology, prevention, treatment services, and recovery research to practice. Proposed studies may target the individual, provider, organizational, community, or system level. This initiative prioritizes replicable and scalable approaches for accelerating the routine use of effective, evidence-based prevention, treatment and recovery interventions and services. The translation of research to practice and research relevant to chronic pain comorbid with substance use is also a priority. Research may deploy a variety of methods and approaches, including but not limited to identifying and characterizing malleable factors, developing and testing interventions and implementation strategies, deploying and testing collaborative data science approaches, and/or developing and testing approaches that integrate the collaboration of researchers and decision-makers at any levels (e.g., clinical-, health system-, public health- or policy-level).
Eligibility
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Files
| File | Type | Posted |
|---|---|---|
| PKG00293059.pdf | ||
| RFA-DA-27-016-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity